ArticleAJOG global reports2026
Defining the mechanisms of neuroinflammation and antepartum neuroprotection in human neural progenitor cells and microglia.
Article in AJOG global reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCorticosteroids and magnesium sulfate are neuroprotective agents that decrease disabilities in children born prematurely. The neuroprotective mechanisms of these drugs remain unclear, and despite widespread use, gestational age remains a major risk factor for fetal neurological injury. Towards full term, the abundance of neural progenitor cells declines, and microglia increase in number. The efficacy of neuroprotective agents may be cell-type specific at the time of prematurity. We hypothesize that the relationship between gestational age and neuroprotection is because of cell-specific responses to antepartum treatments.
objectiveThis study evaluates in vitro inflammatory cytokine production by human fetal microglia and neural progenitor cells exposed to magnesium sulfate and betamethasone to determine the neuroprotective mechanisms of these drugs. STUDY
designCommercially available human fetal microglia (HMC3) and neural progenitor cells (ReNcells) were exposed to interleukin-1 beta, a known instigator of perinatal neuroinflammatory injury. Cells were also given magnesium sulfate, betamethasone, magnesium sulfate and betamethasone, or the vehicle (control) for 24 hours. Inflammatory responses were evaluated by gene expression and Milliplex immunology assay of the cell media to measure cytokine production and secretion.
resultsWith interleukin-1 beta exposure, inflammatory cytokines were upregulated in both cell types according to gene expression and were found at elevated concentrations within cell media. Substantial production of the pro-inflammatory cytokines interleukin-6 and interleukin-8 was observed by both cell types, but only microglia produced the anti-inflammatory cytokine interleukin-10. In interleukin-1 beta exposed neural progenitor cells, treatment with magnesium sulfate slightly lowered interleukin-6 and interleukin-8, but this did not occur with betamethasone or magnesium sulfate/betamethasone. In microglia, betamethasone alone and magnesium sulfate/betamethasone substantially reduced most cytokines upregulated by interleukin-1 beta. A discordance was observed between interleukin-8 expression within microglia and its concentration measured in cell media. Additional analysis revealed that betamethasone reduced the translation of interleukin-8 rather than its extracellular secretion.
conclusionPro-inflammatory cytokine expression and production by microglia and neural progenitor cells were impacted differently by each drug. Microglial responses to interleukin-1 beta were substantially attenuated by betamethasone, whereas magnesium sulfate had a mild influence on neural progenitor cells. Furthermore, our results suggest that the neuroprotective mechanisms of betamethasone may be attributed to the reduction of cytokine translation within microglia. Additional investigation is warranted to elucidate whether neuroprotection is attributed to cell-specific drug interactions at the time of the inciting event.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.